Skip to main content
Journal cover image

Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.

Publication ,  Journal Article
Lee, T-H; Chan, A; Bryan, W; Park, L; Hashem, M; Townsend, M; Moylan, C; Britt, R; Choi, S; Naggie, S
Published in: J Viral Hepat
April 2021

Previous studies have reported an association of proton pump inhibitor (PPI) use and decreased sustained viral response rate (SVR) in patients taking ledipasvir/sofosbuvir (LDV/SOF). The relationship between PPI usage and SVR is less clear in patients with HIV/HCV coinfection, where concomitant antiretrovirals may result in more complex drug interactions. This retrospective study evaluates the effects of acid suppression medications (PPI or H2 -receptor antagonist [H2 B]) use and SVR rates in patients with HIV/HCV or HCV and taking LDV/SOF in a large multicentre veteran cohort. Patients in the Veterans Affairs Health Care System who received LDV/SOF ± ribavirin from 10/10/2014 to 12/31/2015 were included. The odds ratios (OR) of PPI or H2 B use for SVR were adjusted for clinical factors and with inverse probability of treatment weighting for non-random treatment selection for acid suppression medication use. There were 9703 veterans included in our final analysis. After adjustment of other clinical factors, PPI use is associated with a lower SVR in the overall cohort (95.0% vs. 96.1%, OR: 0.86, 95% CI: 0.74-0.99, p = .03, number needed to harm 90.9) and HIV/HCV coinfection subgroup (93.4% vs. 96.9%, OR: 0.47, 95% CI: 0.26-0.85, p = .01, number needed to harm 28.6). This present study reveals PPI use is associated with reduced SVR after LDV/SOF treatment, with a more significant impact in the subgroup of patients with HIV/HCV coinfection. Precautions need to be taken when using PPI and LDV/SOF in this group of patients.

Duke Scholars

Published In

J Viral Hepat

DOI

EISSN

1365-2893

Publication Date

April 2021

Volume

28

Issue

4

Start / End Page

630 / 636

Location

England

Related Subject Headings

  • Veterans
  • Treatment Outcome
  • Sofosbuvir
  • Retrospective Studies
  • Proton Pump Inhibitors
  • Humans
  • Hepatitis C
  • Hepacivirus
  • HIV Infections
  • Gastroenterology & Hepatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, T.-H., Chan, A., Bryan, W., Park, L., Hashem, M., Townsend, M., … Naggie, S. (2021). Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. J Viral Hepat, 28(4), 630–636. https://doi.org/10.1111/jvh.13462
Lee, Tzu-Hao, Austin Chan, William Bryan, Lawrence Park, Mohamed Hashem, Mary Townsend, Cynthia Moylan, Rachel Britt, Steve Choi, and Susanna Naggie. “Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.J Viral Hepat 28, no. 4 (April 2021): 630–36. https://doi.org/10.1111/jvh.13462.
Lee T-H, Chan A, Bryan W, Park L, Hashem M, Townsend M, Moylan C, Britt R, Choi S, Naggie S. Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. J Viral Hepat. 2021 Apr;28(4):630–636.
Journal cover image

Published In

J Viral Hepat

DOI

EISSN

1365-2893

Publication Date

April 2021

Volume

28

Issue

4

Start / End Page

630 / 636

Location

England

Related Subject Headings

  • Veterans
  • Treatment Outcome
  • Sofosbuvir
  • Retrospective Studies
  • Proton Pump Inhibitors
  • Humans
  • Hepatitis C
  • Hepacivirus
  • HIV Infections
  • Gastroenterology & Hepatology